{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:16:45Z","timestamp":1787066205226,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jcjo.2021.06.025","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:04:16Z","timestamp":1627430656000},"page":"66-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Incidence of ocular hypertension after anti-VEGF injections: examining the effect of drug filtration and silicone-free syringes"],"prefix":"10.1016","volume":"58","author":[{"given":"Steven S.","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvir","family":"Koenigstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8136-8477","authenticated-orcid":false,"given":"Travers","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Merkur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-7880","authenticated-orcid":false,"given":"David","family":"Albiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaivon","family":"Pakzad-Vaezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9933-3937","authenticated-orcid":false,"given":"Andrew","family":"Kirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2021.06.025_bib0001","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00417-010-1315-z","article-title":"A review of clinical trials of anti-VEGF agents for diabetic retinopathy","volume":"248","author":"Nicholson","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0002","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"5","author":"Li","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0003","doi-asserted-by":"crossref","first-page":"e78538","DOI":"10.1371\/journal.pone.0078538","article-title":"Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review","volume":"8","author":"Pielen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0004","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/IAE.0b013e3180592ba6","article-title":"Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin)","volume":"27","author":"Falkenstein","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3928\/15428877-20090430-12","article-title":"Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections","volume":"40","author":"Kahook","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0006","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/jop.2009.0076","article-title":"Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections","volume":"26","author":"Adelman","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0007","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents","volume":"95","author":"Good","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0008","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ophtha.2017.11.027","article-title":"The real-world effect of intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS registry","volume":"125","author":"Atchison","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0009","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ophtha.2018.11.019","article-title":"The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of Ophthalmology","volume":"126","author":"Hoguet","year":"2019","journal-title":"Ophthalmology (Rochester, Minn)"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0010","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaophthalmol.2017.0059","article-title":"Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery","volume":"135","author":"Eadie","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0011","series-title":"Abstract presented at: Glaucoma Session - Canadian Ophthalmology Society Annual Meeting","article-title":"Incidence of glaucoma surgeries related to intravitreal anti-VEGF injections","author":"Maes","year":"2020"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0012","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/jop.2014.0062","article-title":"High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism","volume":"31","author":"Ricca","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0013","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1097\/IAE.0000000000001809","article-title":"Contamination of anti-VEGF drugs for intravitreal injection: how do repackaging and newly developed syringes affect the amount of silicone oil droplets and protein aggregates?","volume":"38","author":"Schargus","year":"2018","journal-title":"Retina (Philadelphia, Pa)"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0014","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian Treat-and-Extend Analysis Trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0015","doi-asserted-by":"crossref","first-page":"18021","DOI":"10.1038\/s41598-019-54226-7","article-title":"A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes","volume":"9","author":"Lode","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197670","article-title":"The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration\u2014a cost-effectiveness analysis from a societal perspective","volume":"13","author":"van Asten","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19780","article-title":"A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)","volume":"19","author":"Chakravarthy","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0018","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaophthalmol.2014.3591","article-title":"Evaluation of compounded bevacizumab prepared for intravitreal injection","volume":"133","author":"Yannuzzi","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0019","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamaophthalmol.2015.2556","article-title":"Association of compounded bevacizumab with postinjection endophthalmitis","volume":"133","author":"VanderBeek","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00005237-200501000-00015","article-title":"Maximizing patient safety: filter needle use with glass ampules","volume":"19","author":"Heiss-Harris","year":"2005","journal-title":"J Perinat Neonatal Nurs"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0021","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1111\/j.1755-3768.2011.02278.x","article-title":"Intravitreal ranibizumab, with or without filter?","volume":"90","author":"Montero","year":"2012","journal-title":"Acta Ophthalmologica"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100862","article-title":"Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections","volume":"80","author":"Melo","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0023","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0024","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0025","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0026","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/2474126417735963","article-title":"Silicone oil droplets are more common in fluid from BD insulin syringes as compared to other syringes","volume":"1","author":"Emerson","year":"2017","journal-title":"J VitreoRetin Dis"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0027","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.oret.2020.07.021","article-title":"Prospective study of silicone oil microdroplets in eyes receiving intravitreal anti-vascular endothelial growth factor therapy in 3 different syringes","volume":"5","author":"Thompson","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0028","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/IAE.0b013e31816c6868","article-title":"Intravitreal silicone oil droplets after intravitreal drug injections","volume":"28","author":"Bakri","year":"2008","journal-title":"Retina (Philadelphia, Pa)"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0029","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0030","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/IAE.0b013e3181d50cea","article-title":"High-molecular-weight aggregates in repackaged bevacizumab","volume":"30","author":"Kahook","year":"2010","journal-title":"Retina (Philadelphia, Pa)"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0031","series-title":"The American Society of Retina Specialists. Avella releases comment on Avastin order backlog","year":"2021"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0032","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0083-6729(09)81003-0","article-title":"Biosynthesis of oleamide","volume":"81","author":"Mueller","year":"2009","journal-title":"Vitam Horm"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0033","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/IAE.0000000000002947","article-title":"Particulate matter from syringes used for intravitreal injections","volume":"41","author":"Dounce","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0034","doi-asserted-by":"crossref","first-page":"13248","DOI":"10.1038\/s41598-020-70269-7","article-title":"The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis","volume":"10","author":"de Vries","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0035","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ophtha.2016.02.046","article-title":"Comprehensive review of ocular and systemic safety events with intravitreal aflibercept injection in randomized controlled trials","volume":"123","author":"Kitchens","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0036","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/OPTH.S232548","article-title":"Incidence of glaucoma or ocular hypertension after repeated anti-vascular endothelial growth factor injections for macular degeneration","volume":"13","author":"Wingard","year":"2019","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0037","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/bjophthalmol-2015-307595","article-title":"Changes in intraocular pressure in study and fellow eyes in the IVAN trial","volume":"100","author":"Foss","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0038","first-page":"2156","article-title":"Human trabecular meshwork phagocytosis. Observations in an organ culture system","volume":"31","author":"Buller","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0039","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1442-9071.2009.01920.x","article-title":"Pigment dispersion syndrome and pigmentary glaucoma\u2014a major review","volume":"36","author":"Niyadurupola","year":"2008","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0040","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/jop.2019.0042","article-title":"Bevacizumab for intravitreal injection: impact of sub-visible particles on the shelf-life of repackaged bevacizumab","volume":"35","author":"Crul","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2021.06.025_bib0041","first-page":"70","article-title":"Stability assessment of repackaged bevacizumab for intravitreal administration","volume":"19","author":"Pereboom","year":"2015","journal-title":"Int J Pharm Compd"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418221002519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418221002519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:11:01Z","timestamp":1757794261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418221002519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0008418221002519"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2021.06.025","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of ocular hypertension after anti-VEGF injections: examining the effect of drug filtration and silicone-free syringes","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2021.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}